drugset
drugset / Trial / NCT04594252

Copper Balance in Healthy Participants Administered ALXN1840

NCT04594252 ↗

Phase 1 Completed 17 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The study will assess the change from baseline in mean daily copper balance in healthy participants with repeat-dose administrations of ALXN1840 over 2 weeks.

Timeline

Start
2020-07-01
Primary completion
2020-11-18
Completion
2020-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule 30 mg Oral

Indications

No indication recorded.